Profiel
Ronald Marcus is former Senior Vice President-Medical at Karuna Therapeutics, Inc., former Chief Medical Officer & Head-Regulatory Affairs at Avalo Therapeutics, Inc., former Chief Medical Officer at Terran Biosciences, former Executive Director-Global Clinical Research at Bristol Myers Squibb Co. and former Chief Medical Officer at Spinifex Pharmaceuticals Pty Ltd.
Ronald Marcus received an undergraduate degree from the University of Virginia and a doctorate from State University of New York at Buffalo.
Eerdere bekende functies van Ronald Marcus
Bedrijven | Functie | Einde |
---|---|---|
KARA THER | Chief Tech/Sci/R&D Officer | 18-03-2024 |
Terran Biosciences
Terran Biosciences BiotechnologyHealth Technology Terran Biosciences is a biotech platform company that focuses on developing therapeutics and technologies for patients with neurological and psychiatric diseases. Terran Biosciences is based in New York, NY and has subsidiaries in the United States. The company has built a CNS-focused, tech-enabled drug development platform and is advancing a number of assets that include a late-stage therapeutic for schizophrenia, an FDA-cleared neuroimaging software platform, and a drug design engine that has generated first-in-class and psychedelic-based therapeutics. The company was founded by Samuel Clark, who has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | 01-10-2020 |
AVALO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17-11-2017 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-11-2013 |
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Ronald Marcus
University of Virginia | Undergraduate Degree |
State University of New York at Buffalo | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
Terran Biosciences
Terran Biosciences BiotechnologyHealth Technology Terran Biosciences is a biotech platform company that focuses on developing therapeutics and technologies for patients with neurological and psychiatric diseases. Terran Biosciences is based in New York, NY and has subsidiaries in the United States. The company has built a CNS-focused, tech-enabled drug development platform and is advancing a number of assets that include a late-stage therapeutic for schizophrenia, an FDA-cleared neuroimaging software platform, and a drug design engine that has generated first-in-class and psychedelic-based therapeutics. The company was founded by Samuel Clark, who has been the CEO since incorporation. | Health Technology |